Xenon Pharmaceuticals Inc
XENE
NASDAQ
Biotechnology
$62.35
USD
-1.88 (-2.93%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.21B
Volume 913.5K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-409.19M
TTM
-47.1%
YoY
Operating Cash Flow
$-337.52M
TTM
-46.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 19.2 | 19.3 | 22.1 | 23.8 | 23.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 94.2 | 96.3 | 109.8 | 112.3 | 123.2 |
Operating Income | -94.2 | -96.3 | -109.8 | -112.3 | -123.2 |
EBITDA | -93.6 | -95.7 | -109.2 | -111.7 | -122.6 |
Other Income / Expense | 1.7 | -0.1 | -0.3 | 0.5 | -0.3 |
Total Other Income / Expense | 8.9 | 6.1 | 5.0 | 7.5 | 11.8 |
Income Before Income Taxes | -85.3 | -90.2 | -104.7 | -104.9 | -111.3 |
Income Taxes | -0.6 | 0.7 | 0.5 | -2.6 | -0.6 |
Net Income | -84.7 | -90.9 | -105.3 | -102.3 | -110.7 |
Consolidated Net Income / Loss | -84.7 | -90.9 | -105.3 | -102.3 | -110.7 |
Net Income Attributable to Common Shareholders | -84.7 | -90.9 | -105.3 | -102.3 | -110.7 |
Basic EPS | -$1.07 | -$1.15 | -$1.31 | -$1.17 | -$1.11 |
Diluted EPS | -$1.07 | -$1.15 | -$1.31 | -$1.17 | -$1.11 |
Basic Shares Outstanding | 79.0M | 79.2M | 80.1M | 87.3M | 99.6M |
Diluted Shares Outstanding | 79.0M | 79.2M | 80.1M | 87.3M | 99.6M |